Translational cancer research
Our group has been focused for years on the identification, characterization and validation, through multidisciplinary approaches, of prognostic/predictive markers and potential therapeutic targets in tumors, in particular breast, gynecological carcinomas and sarcomas. An additional group goal is to gain insights into the molecular basis of chemo/radioresistance in cancer and to advance in the design of new, more effective and less toxic antitumor (nano)-therapies. Among our studies, we highlight those focused on analyzing the functional role in cancer of the chromosomal instability, cell cycle, mechanisms of cell death, intratumoral heterogeneity and the immune response to tumors.
Group leader
Gema Moreno Bueno
Principal Investigator
- Guillermo de Cárcer Díez
- Ricardo Sánchez Prieto
Collaborating Staff
- Ángela Montes San Lorenzo
- Carmen Ramos Nebot
- Borja Belandia Gómez
- Cristina Garnés García
- Cristina Susín Lara
- Eva Díaz Martín
- Francisco José Cimas Felipe
- Ignacio Marina Bueno
- José David Sarrió López
- José Ignacio Klett Mingo
- Lucía Pascual Antón
- María Escribano Cebrián
- María José Ruíz Hidalgo
- Natalia Sanz Gómez
- Saleta Morales Dolores
- Sara Lázaro Encinas
- Sara Colomo del Pino
- Sandra Ballesteros Sánchez
- Sara Oltra Sanchís
Principal Investigator
- Guillermo de Cárcer Díez
- Ricardo Sánchez Prieto
Collaborating Staff
- Ángela Montes San Lorenzo
- Carmen Ramos Nebot
- Borja Belandia Gómez
- Cristina Garnés García
- Cristina Susín Lara
- Eva Díaz Martín
- Francisco José Cimas Felipe
- Ignacio Marina Bueno
- José David Sarrió López
- José Ignacio Klett Mingo
- Lucía Pascual Antón
- María Escribano Cebrián
- María José Ruíz Hidalgo
- Natalia Sanz Gómez
- Saleta Morales Dolores
- Sara Lázaro Encinas
- Sara Colomo del Pino
- Sandra Ballesteros Sánchez
- Sara Oltra Sanchís
Strategic objectives
- To identify new resistance mechanisms to anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy and targeted therapies).
- To study the molecular events associated with tumor invasion and metastasis.
- To validate new prognostic/predictive biomarkers in cancer.
- To characterize new therapeutic approaches and/or evaluate the repositioning of drugs to target specific predictive biomarkers in cancer.
- To investigate the role of the immune system in the clinical behavior of breast and gynecological tumors.
- To unravel the role of the intratumoral heterogeneity and its impact on the clinical behavior of solid tumors.
Research lines
- Identification and characterization of new mechanisms of resistance to cancer therapy.
- Analysis of intratumoral heterogeneity in cancer.
- Search for new diagnostic markers in cancer.
- New therapeutic targets in cancer.
Location
Madrid Autonomous University
Translational Cancer Research Laboratory
Department of Biochemistry-Faculty of Medicine
Sols-Morreale Biomedical Research Institute
Phone: +34 91 497 8974
gmoreno@iib.uam.es
Keywords
Intratumoral heterogeneity, Chromosomal instability, Cell cycle, Cell death, Resistance, Targeted therapies, Nanomedicine, Anti-tumor immune response, MAPK, Cell signaling, Breast cancer, Gynecological cancer, Sarcoma.